BioGenes announces management buy-out
The MBO will support future growth by driving innovations for customers and building new strategic partnerships to further expand market position as a leader in host cell assay development.
BioGenes has acquired all outstanding shares from its existing shareholders GUB Unternehmensbeteiligungen GmbH & Co. KGaA and VC Fonds Berlin GmbH for an undisclosed price. The management team consisting of the two founders Dr Alexander Knoll and Dr Sergej Ovodov have taken over these shares in a management buy-out (MBO). The acquisition was been finalized on 31 October 2015.
Dr Alexander Knoll, Managing Director of BioGenes said: "We are delighted to have reached an agreement with the previous shareholders and we would like to take the opportunity to thank them for their loyalty. With their support, BioGenes has been growing strongly over the last years. The MBO will support our future growth strategy by driving innovations for customers and building new strategic partnerships with the aim to further expand our market position as a leader in host cell assay development."
Dagmar Schwertner, Marketing Director of BioGenes said: “BioGenes is known as a trusted and experienced expert in immunoassay, 2D electrophoresis and antibody development and we intend to continue systematically down the path we have started on. High quality standards throughout the whole value chain will of course be ensured in the years ahead.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.